Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial

What Was Tested

This randomized controlled trial paper looks at Anamorelin (non-peptide).

Anamorelin (ONO-7643) is a novel selective ghrelin receptor agonist under development for treating cancer cachexia.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

The participants were allocated by chance, so the Anamorelin (non-peptide) group and the comparison group should start out alike.

Neither the participants nor the staff measuring them knew who was on Anamorelin (non-peptide), so expectations could not easily colour the readings.

Some participants received a placebo instead of Anamorelin (non-peptide), giving a reference point.

The timeline in the abstract includes 12 weeks.

The co-primary endpoints were the changes from baseline over 12 weeks in LBM and handgrip strength (HGS).

Secondary endpoints included body weight, QOL, Karnofsky Performance Scale (KPS), and serum biomarkers.

What Was Measured

PubMed files the paper under topics including Cachexia, Carcinoma, Non-Small-Cell Lung, Hydrazines, Lung Neoplasms, Oligopeptides, Prognosis and Quality of Life.

Author keywords: Anamorelin (ONO-7643), Lean body mass, Non-small cell lung cancer and Randomized controlled trial.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Anamorelin (non-peptide) over 12 weeks.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2016 (Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer), a journal based in Germany.

More context: the Anamorelin (non-peptide) compound page, all human trials.